



PTO/SB/81 (04-05)

**POWER OF ATTORNEY  
and  
CORRESPONDENCE ADDRESS  
INDICATION FORM**

Application Number	10/751,274
Filing Date	December 31, 2003
First Named Inventor	Antoni Kozlowski, et al.
Title	HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS
Art Unit	1713
Examiner Name	ROBAGO, Roberto
Attorney Docket Number	SHE0063 / 6800-0063

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

☒ Practitioners associated with the Customer Number:

**21968**

**AND**

☒ Practitioner(s) named below:

Name	Registration Number
Roberta L. Robins	33,208
Dahna S. Pasternak	41,411
Susan T. Evans	38,443
Jenny Buchbinder	48,588

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The address associated with the above-mentioned Customer Number:

OR

☐ The address associated with Customer Number:

OR

☐ Firm or  
Individual Name

Address

City

State

Zip

Country

Telephone

Email

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

**SIGNATURE of Applicant or Assignee of Record**

Signature

*Mark A. Wilson*

Date

*June 26, 2006*

Name

Mark A. Wilson

Telephone

650-620-5506

Title and Company

Director, Intellectual Property

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☒ \*Total of One forms are submitted.



PTO/SB/95 (09-04)

Attorney Docket No. SHE0063

**STATEMENT UNDER 37 CFR 3.73(b)**Inventor/Applicant: Nektar Therapeutics AL CorporationApplication No./Patent No.: 10/751,274 Filed/Issue Date: December 31, 2003Entitled: HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS

Nektar Therapeutics AL Corporation, a corporation  
 (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or  
 2. ☐ an assignee of less than the entire right, title and interest.  
 The extent (by, percentage) of its ownership interest is \_\_\_\_\_ %

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 014395, Frame 0902, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
 The document was recorded in the United States Patent and Trademark Office at  
 Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
2. From: \_\_\_\_\_ To: \_\_\_\_\_  
 The document was recorded in the United States Patent and Trademark Office at  
 Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
 The document was recorded in the United States Patent and Trademark Office at  
 Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Mark A. Wilson  
 Signature

June 26, 2006  
 Date

Mark A. Wilson  
 Printed or Typed Name

650-620-5506  
 Telephone Number

Director, Intellectual Property  
 Title